833 abstracts found.



Results filter

Are patients interested in clinical trials? An update from CancerHelp UK

Year:

Session type:

Claire Connolly1, Liz Woolf1
1Cancer Research UK, London, UK

Prognostic significance of hypoxia-inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab

Year:

Session type:

James Powell1, Stefan Dojcinov2, Louise King2, Sue Wosniak2, Stephen Gerry3, Angela Casbard3, Hazel Bailey1, Eve Gallop-Evans1, Tim Maughan4
1Velindre Cancer Centre, Cardiff, UK, 2University Hospital of Wales, Cardiff, UK, 3Wales Cancer Trials Unit, Cardiff, UK, 4Gray Institute for Radiation Oncology & Biology, University of Oxford, Oxford, UK

Anti-HER anibodies encapsulated redispersible nanoparticles of Sugar Based PLGA based Polymeric nanoparticles of Tamoxifen citrate and their cellular uptake and cytotoxicity studies in MCF-7

Year:

Session type:

Aftab Alam1, Sushama Talegaonkar1, Amulya K Panda2, Parsad Adamane2, Dinesh G Goswami2, Zeenat Iqbal1
1Jamia Hamdard, Delhi, India, 2National Institute of Immunology, Delhi, India

Update on renal cancer: UK recruitment into key head-to-head trials comparing drugs for the management of 1st line metastatic renal cell cancer

Year:

Session type:

Robert Hawkins1
1The Christie NHS Foundation Trust and The University of Manchester, Manchester, UK

Patterns of breast cancer recurrence and associated health care costs of 1000 patients: a longitudinal study.

Year:

Session type:

Lucy Walkington1, Alex Newsham1, Luis Deverede1, Mehran Afshar1, Peter Hall1, Tim Perren1, David Dodwell1, James Thomas1, Adam Glaser1, Geoff Hall1
1St James's Institute of Oncology, Leeds, UK

Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up.

Year:

Session type:

Suneil Jain1, Andrew Loblaw1, Danny Vesprini1, Vibhuti Jethava1, Perakaa Sethukavalan1, Alexandre Mamedov1, Laurence Klotz1
1Sunnybrook Odette Cancer Centre, Toronto, Canada

Ovarian cancer recurrence and associated health care costs: A longitudinal 5-year study

Year:

Session type:

Mehran Afshar1, Alexander Newsham1, Luis Daverede1, Lucy Walkington1, Peter Hall1, James Thomas1, Alison Young1, David Jackson1, Timothy Perren1, Adam Glaser1, Geoff Hall1
1St. James Institute Of Oncology, Leeds, UK

The pattern and timing of disease recurrence in squamous cancer of the anus: Mature results from the NCRI ACT II trial

Year:

Session type:

David Sebag-Montefiore1, Roger James2, Helen Meadows3, Rubina Begum3, David Cunningham4, John Northover5, Jonathan Lederman6,3, Sandra Beare3, Latha Kadalayil3, Robert Glynne-Jones7
1University of Leeds St James's Institute of Oncology, Leeds, UK, 2Maidstone Hospital, Maidstone, UK, 3CRUK and UCL Cancer Trials Centre, London, UK, 4Royal Marsden Hospital, London, UK, 5St. Marks Hospital, Harrow, UK, 6UCL Cancer Institute and UCL Hospitals, London, UK, 7Mount Vernon Centre for Cancer Treatment, Middlesex, UK

Comparison of the rate of KRAS mutation testing in the UK and Europe in colorectal cancer

Year:

Session type:

Harpreet Wasan1, Jonathan Maddern2, Richard Wilson3
1Hammersmith Hospital, London, UK, 2Merck Serono, London, UK, 3Queen's University Belfast, Northern Ireland, UK

KIAA0020 as a potential proliferative target for triple-negative breast cancer

Year:

Session type:

Elodie Noël1, Anita Grigoriadis1, Fara Brasó Maristany1, Vandna Shah1, Patrycja Gazinska1, Emanuele de Rinaldis1, Pierfrancesco Marra1, Andrew Tutt1
1King's College London, London, UK

Page 25 of 84« First...25...50...Last »